melanotan-2 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-19 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
==== European investigations ==== In 2000 a study to address the concerns regarding cardiovascular safety was requested by the EMA, and the makers agreed to perform post-marketing a long-term cardiovascular morbidity/mortality study in patients on rosiglitazone in combination with a sulfonylurea or metformin: the RECORD study. The results as published in 2009 showed non-inferiority with regard to cardiovascular events and cardiovascular death when the treatment with rosiglitazone was compared with metformin or a sulfonylurea. For myocardial infarction, there was a non-statistically significant increase in risk. In their assessment, the European regulators acknowledged weaknesses of the study, such as an unexpectedly low rate of cardiovascular events and the open-label design, which may lead to reporting bias. They found that the results were inconclusive. The European Medicines Agency recommended on 23 September 2010 that Avandia be suspended from the European market. According to a probe by the British Medical Journal in September 2010, the United Kingdom's Commission on Human Medicines recommended to the Medicines and Healthcare Products Regulatory Agency (MHRA) back in July 2010, to withdraw Avandia sale because its "risks outweigh its benefits". Additionally, the probe revealed that in 2000, members of the European panel in charge of reviewing Avandia prior to its approval had concerns about the long-term risks of the drug.
Hashim Thaçi (born 24 April 1968) is a Kosovan politician who was the first prime minister of Kosovo (2008–2014) and the foreign minister and deputy prime minister (2014–2016) in the cabinet led by Isa Mustafa. He also served as president of Kosovo from 2016 until his resignation in 2020. Thaçi is from the region of Drenica in Kosovo, which is where the Kosovo Liberation Army (KLA) originated. He studied philosophy in Pristina before moving to Switzerland, where he joined the KLA in 1993. An Albanian nationalist, he rose through the ranks of the KLA to become leader of the most powerful faction by 1999, during the Rambouillet negotiations. He then joined the interim Kosovo administration after the war. Thaçi became leader of the Democratic Party of Kosovo (PDK), which won the largest share of the vote in the 2007 Kosovo elections. In 2008, Thaçi read the declaration of independence of Kosovo and became its first prime minister. In 2016 he was elected president of Kosovo. Thaçi pursued a pro-American policy while in office. In September 2026, Thaçi was convicted by the Kosovo Specialist Chambers' first instance Trial Panel of war crimes in the Kosovo War. Thaçi's defence lawyers stated that they would appeal the decision. In 2020, the Kosovo Specialist Chambers and Specialist Prosecutor's Office in The Hague filed a ten-count indictment against Thaçi and others, charging them with crimes against humanity and war crimes. To face these charges, Thaçi resigned from the presidency, stating that he did so to "protect the integrity of the presidency of Kosovo".
Tribenoside (Glyvenol) is a vasoprotective drug used to treat hemorrhoids. It has mild anti-inflammatory, analgesic, and wound healing properties. Tribenoside stimulates laminin α5 production and laminin-332 deposition to help repair the basement membrane during the wound healing process. It is a mixture of the α- and β-anomers. Tribenoside has been shown to induce drug hypersensitivity syndrome in association with CMV reactivation.
The United States and the Soviet Union engaged in competition vis-à-vis the arts. Cultural competition played out in Moscow, New York, London, and Paris. In 1946 America opened an exhibition called 'Advancing American Art' which gained popularity with the aims of expressing American art, in response the Soviets opened a respective exhibition showcasing Soviet Realism. The Soviets excelled at ballet and chess, the Americans at jazz and abstract expressionist paintings. The US funded its own ballet troupes, and both used ballet as political propaganda, using dance to reflect life style in the "battle for the hearts and minds of men." The defection of a premier dancer became a major coup. Chess was inexpensive enough—and the Russians always won until America unleashed Bobby Fischer. Vastly more expensive was the Space Race, as a proxy for scientific supremacy (with a technology with obvious military uses). As well when it came to sports the two countries both competed in the Olympics during the Cold War period which also created severe tension when the West boycotted the first Russian Olympics in 1980.
Sources: en.wikipedia.org
== 1971–88 == South Africa was the indirect cause of the 1976 Olympic boycott. A New Zealand rugby union tour of South Africa prompted African countries to demand that the New Zealand Olympic team be excluded from the games. The IOC demurred on the grounds that rugby union was not an Olympic sport and the New Zealand Rugby Union was not affiliated to the New Zealand Olympic Committee. Of 28 African invitees, 26 boycotted the Games, joined by Iraq and Guyana. South Africa continued to compete at the (Summer) Paralympics until excluded by the Dutch government from the 1980 Games. The country had a racially desegregated parasport team from 1975. South Africa was expelled from the International Paralympic Committee in 1985. The IOC adopted a declaration against "apartheid in sport" on 21 June 1988, for the total isolation of apartheid sport.
thymidine (T, dT) Also deoxythymidine. One of the four standard nucleosides used in DNA molecules, consisting of a thymine base with its N9 nitrogen bonded to the C1 carbon of a deoxyribose sugar. The prefix deoxy- is commonly omitted, since there are no ribonucleoside analogs of thymidine used in RNA, where it is replaced with uridine instead.
He prevailed over Etcheverry in four sets to reach his third consecutive semi-final at this tournament. He fell in his semi-final match to world No. 4 and last year finalist, Casper Ruud, in straight sets. Zverev began his grass season by withdrawing from the BOSS Open in Stuttgart due to a thigh injury that he picked up during his semifinal match at Roland Garros. Zverev then defeated Dominic Thiem, Denis Shapovalov, and Nicolas Jarry in Halle to reach the semifinals where he lost to eventual champion Alexander Bublik. At Wimbledon, Zverev lost in third round to Matteo Berrettini. In Båstad, Zverev lost in the quarterfinals to Andrey Rublev. Zverev won the Hamburg European Open, defeating Laslo Djere in the final. His triumph marked his 20th career ATP Title. During his 2023 US Open match against Jannik Sinner, Zverev halted play and complained to officials in response to a fan shouting the opening stanza to "Deutschlandlied", a song which has served as the national anthem of Germany; the use of the first and second stanza are presently commonly discouraged because of history. Alexander Zverev interpreted this as carrying Nazi sentiment and told officials that the fan had shouted, "the most famous Hitler phrase". Zverev lost the quarterfinals match against Carlos Alcaraz after winning a 4-hour 40 minutes five-set match against Jannik Sinner. This match, in combination with the Roland Garros 2023 semi-final, cemented Zverev's return to top form. His performance in the Asian swing was marked by his 21st title in Chengdu, defeating Roman Safiullin in three sets.
Rebellions in the former Cossack territories erupted occasionally during the interwar period. In 1920–1921, disgruntlement with continued Soviet grain-requisitioning activities provoked a series of revolts among Cossack and outlander communities in South Russia. The former Cossack territories of South Russia and the Urals also experienced a devastating famine in 1921–1922. In 1932–1933, another famine, known as the Holodomor, devastated Ukraine and some parts of South Russia, causing a population decline of about 20–30%. While urban areas were less affected, the decline was even higher in the rural areas, populated largely by Cossacks. Robert Conquest estimates the number of famine-related deaths in the Northern Caucasus at about one million. Government officials expropriated grain and other produce from rural Cossack families, leaving them to starve and die. Many families were forced from their homes in the severe winter and froze to death. Mikhail Sholokhov's letters to Joseph Stalin document the conditions and widespread deaths, as do eyewitness accounts. Besides starvation, the collectivization and dekulakization campaigns of the early 1930s threatened Cossacks with deportation to labor camps, or outright execution by Soviet security organs. In April 1936, the Soviet regime began to relax its restrictions on Cossacks, allowing them to serve openly in the Red Army. Two existing cavalry divisions were renamed as Cossack divisions, and three new Cossack cavalry divisions were established.
== Erythrocytes == Several deficiencies in the level of activity (not function) of glucose-6-phosphate dehydrogenase have been observed to be associated with resistance to the malarial parasite Plasmodium falciparum among individuals of Mediterranean and African descent. The basis for this resistance may be a weakening of the red cell membrane (the erythrocyte is the host cell for the parasite) such that it cannot sustain the parasitic life cycle long enough for productive growth.
Sources: en.wikipedia.org
== External links == Databases Drug metabolism database Directory of P450-containing Systems Drug metabolism Drug metabolism portal Small Molecule Drug Metabolism "Activation, Metabolic". Medical Subject Headings. National Library of Medicine. MeSH D065767. Retrieved 2026-05-24. "Inactivation, Metabolic". Medical Subject Headings. National Library of Medicine. MeSH D008658. Retrieved 2026-05-24. "Biotransformation". Medical Subject Headings. National Library of Medicine. MeSH D001711. Retrieved 2026-05-24.
A lack of economy of size: as most fine chemicals are produced in quantities of less than a few 10 tons per year in multipurpose plants, there is little or no economy of size. The reactor trains of these plants are similar throughout the industry. Regardless of the size of the companies, their main constituents, the reaction vessels, have a median size of 4–6 m3 (140–210 cubic feet). Various products are made throughout a year in campaigns. Therefore, the unit cost per m3 per hour rarely varies with the size of the company. A dichotomy between ownership and management: the company's shares are listed on stock exchanges, and their performance is scrutinized by the financial community. Postponement of a single important shipment can affect a quarterly result. In the small and mid-sized companies, the owners are typically the major shareholders, often members of the same family. Their shares are not traded publicly and fluctuations in their financial performance are more easily coped with. Complicated business processes: flexibility and responsiveness are in jeopardy. Customer complaints, for instance, are difficult to resolve in a straightforward manner. A heterogeneous portfolio of small companies, accumulated over time through M&A activities. The key functions, such as production, R&D, and M&S, are located on different sites, often in different countries. Cohabitation with other units. A comprehensive list of about 1400 fine chemical companies (including traders) can be found in the "event catalogue" of the CPhI exhibition.
== Medical uses == Meprobamate is indicated for the short-term relief of anxiety, although whether the purported anxiolytic effects of meprobamate are separable from its sedative effects is not known. Its effectiveness as a selective agent for the treatment of anxiety has not been proven in humans, and is not used as often as the benzodiazepines for this purpose. Meprobamate is available in 200- and 400-mg tablets for oral administration. It is also a component of the combination drug Equagesic (discontinued in the UK in 2002), acting as a muscle relaxant.
== Later research == Reichelt published a number of papers concluding that autistic children excrete higher levels of peptides in their urine, as well as that such peptides may cause autistic gaze aversion; specifically, by interfering with corticothalamocortical processing of visual stimuli. As a result of this theory, others, particularly Panksepp, have speculated that opioid antagonists such as naloxone and naltrexone may be useful in the treatment of autism. In addition, Christopher Gillberg of the University of Gothenburg has published some studies showing that animals treated with opiates exhibit less clinging, in line with the behavior of autistic children, who, his research has also shown, "do not seem concerned when their parents are not near" and "exhibit less crying than infants without autism", and has also linked an excess of endogenous opioids to stereotypic (i.e. repetitive) behavior. However, more recently, two studies were published which failed to find a difference in levels of peptides in the urine of autistic children as opposed to those without autism. A 2009 review found that no evidence exists that urinary peptide levels are correlated with gut permeability.
=== Structural proteomics === A third area of Borchers' research is structural proteomics, which combines protein chemistry methods—such as cross-linking, hydrogen–deuterium exchange and photoaffinity labelling—with mass spectrometry and molecular modelling to study protein structure and interactions. This work includes the study of protein folding and misfolding associated with diseases such as Parkinson's disease and cystic fibrosis. In 2011, Borchers co-founded the Symposium on Structural Proteomics with Evgeniy Petrotchenko, and the two have co-organized the international meeting annually since.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.